secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0000950103-24-018479
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 8.01, 3.02, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement
--------------------------------------------------------------------------------

- Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.
- Phase 1/2 pivotal study: >50% of patients achieved Complete Response; >85% had fewer surgeries in year post-treatment.
- Raised $79M gross from sale of 8% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52.7M shares at $0.75.
- Investors include Randal Kirk, Patient Capital Management, Bill Miller; proceeds for working capital and general corporate purposes.
- Cash runway extends into 2026, beyond potential commercial launch in H2 2025 if PRGN-2012 is approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324018479/0000950103-24-018479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324018479/dp222802_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-018479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer